Technical Analysis for ATNWW - Actinium Pharmaceuticals Inc WT Ser B Exp 09/03/

Grade Last Price % Change Price Change
grade F 0.18 -18.18% -0.0400
ATNWW closed down 18.18 percent on Thursday, September 12, 2019, on 11 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical ATNWW trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
MACD Bullish Signal Line Cross Bullish -18.18%
Narrow Range Bar Range Contraction -18.18%
Wide Bands Range Expansion -18.18%
Gapped Up Strength -18.18%
MACD Bearish Signal Line Cross Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%

Older signals for ATNWW ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
Medicine RTT Medical Specialties Clinical Medicine Biopharmaceutical Cancers Leukemia Multiple Myeloma Acute Myeloid Leukemia Hematopoietic Stem Cell Transplantation Bone Marrow Transplant Actimab Camidanlumab Tesirine Cd135 Refractory Acute Myeloid Leukemia Refractory Multiple Myeloma Therapies For Patients With Cancers
Is ATNWW a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 0.55
52 Week Low 0.0201
Average Volume 45,585
200-Day Moving Average 0.0
50-Day Moving Average 0.368
20-Day Moving Average 0.241
10-Day Moving Average 0.212
Average True Range 0.107
ADX 48.61
+DI 16.036
-DI 49.029
Chandelier Exit (Long, 3 ATRs ) 0.129
Chandelier Exit (Short, 3 ATRs ) 0.3411
Upper Bollinger Band 0.3596
Lower Bollinger Band 0.1224
Percent B (%b) 0.24
BandWidth 98.423237
MACD Line -0.0479
MACD Signal Line -0.0492
MACD Histogram 0.0012
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1800
Resistance 3 (R3) 0.1800 0.1800 0.1800
Resistance 2 (R2) 0.1800 0.1800 0.1800 0.1800
Resistance 1 (R1) 0.1800 0.1800 0.1800 0.1800 0.1800
Pivot Point 0.1800 0.1800 0.1800 0.1800 0.1800
Support 1 (S1) 0.1800 0.1800 0.1800 0.1800 0.1800
Support 2 (S2) 0.1800 0.1800 0.1800 0.1800
Support 3 (S3) 0.1800 0.1800 0.1800
Support 4 (S4) 0.1800